Challenging the FDA black box warning for high aspirin dose with ticagrelor in patients with diabetes

James J. DiNicolantonio, Victor L. Serebruany

Research output: Contribution to journalArticle

Abstract

Ticagrelor, a novel reversible antiplatelet agent, has a Food and Drug Administration (FDA) black box warning to avoid maintenance doses of aspirin (ASA) .100 mg/daily. This restriction is based on the hypothesis that ASA doses .100 mg somehow decreased ticagrelor's benefit in the Platelet Inhibition and Patient Outcomes (PLATO) U.S. cohort. However, these data are highly postrandomized, come from a very small subgroup in PLATO (57% of patients in the U.S. site), and make no biological sense. Moreover, the ticagrelor-ASA interaction was not significant by any multivariate Cox regression analyses. The Complete Response Review for ticagrelor indicates that for U.S. PLATO patients, an ASA dose .300 mg was not a significant interaction for vascular outcomes. In the ticagrelor-ASA .300 mg cohort, allcause and vascular mortality were not significantly increased (hazard ratio [HR] 1.27 [95% CI 0.84-1.93], P = 0.262 and 1.39 [0.87-2.2], P = 0.170), respectively. Furthermore, for major adverse cardiovascular events (MACEs), 30-day all-cause mortality, and 30-day vascular mortality, the strongest interaction is the diabetes-ASA interaction. That is, patients who had diabetes had significantly fewer MACEs through study end (0.49 [0.34- 0.63], P <0.0001), significantly less 30-day all-cause mortality (0.33 [0.20-0.56], P <0.0001), and significantly less 30-day vascular mortality (0.35 [0.22-0.55], P <0.0001), respectively, when given high-dose (300-325 mg) ASA, regardless of treatment (clopidogrel or ticagrelor) assignment. The black box warning for the use of maintenance ASA doses .100 mg with ticagrelor is inappropriate for patients with diabetes and not evidence based.

Original languageEnglish (US)
Pages (from-to)669-671
Number of pages3
JournalDiabetes
Volume62
Issue number3
DOIs
StatePublished - Mar 2013
Externally publishedYes

Fingerprint

Drug Labeling
United States Food and Drug Administration
Aspirin
Blood Vessels
Mortality
clopidogrel
Platelet Aggregation Inhibitors
Ticagrelor
Blood Platelets
Regression Analysis
Maintenance

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Challenging the FDA black box warning for high aspirin dose with ticagrelor in patients with diabetes. / DiNicolantonio, James J.; Serebruany, Victor L.

In: Diabetes, Vol. 62, No. 3, 03.2013, p. 669-671.

Research output: Contribution to journalArticle

DiNicolantonio, James J. ; Serebruany, Victor L. / Challenging the FDA black box warning for high aspirin dose with ticagrelor in patients with diabetes. In: Diabetes. 2013 ; Vol. 62, No. 3. pp. 669-671.
@article{85fc266311654099a68aa3ba4fb7f2f4,
title = "Challenging the FDA black box warning for high aspirin dose with ticagrelor in patients with diabetes",
abstract = "Ticagrelor, a novel reversible antiplatelet agent, has a Food and Drug Administration (FDA) black box warning to avoid maintenance doses of aspirin (ASA) .100 mg/daily. This restriction is based on the hypothesis that ASA doses .100 mg somehow decreased ticagrelor's benefit in the Platelet Inhibition and Patient Outcomes (PLATO) U.S. cohort. However, these data are highly postrandomized, come from a very small subgroup in PLATO (57{\%} of patients in the U.S. site), and make no biological sense. Moreover, the ticagrelor-ASA interaction was not significant by any multivariate Cox regression analyses. The Complete Response Review for ticagrelor indicates that for U.S. PLATO patients, an ASA dose .300 mg was not a significant interaction for vascular outcomes. In the ticagrelor-ASA .300 mg cohort, allcause and vascular mortality were not significantly increased (hazard ratio [HR] 1.27 [95{\%} CI 0.84-1.93], P = 0.262 and 1.39 [0.87-2.2], P = 0.170), respectively. Furthermore, for major adverse cardiovascular events (MACEs), 30-day all-cause mortality, and 30-day vascular mortality, the strongest interaction is the diabetes-ASA interaction. That is, patients who had diabetes had significantly fewer MACEs through study end (0.49 [0.34- 0.63], P <0.0001), significantly less 30-day all-cause mortality (0.33 [0.20-0.56], P <0.0001), and significantly less 30-day vascular mortality (0.35 [0.22-0.55], P <0.0001), respectively, when given high-dose (300-325 mg) ASA, regardless of treatment (clopidogrel or ticagrelor) assignment. The black box warning for the use of maintenance ASA doses .100 mg with ticagrelor is inappropriate for patients with diabetes and not evidence based.",
author = "DiNicolantonio, {James J.} and Serebruany, {Victor L.}",
year = "2013",
month = "3",
doi = "10.2337/db12-0746",
language = "English (US)",
volume = "62",
pages = "669--671",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "3",

}

TY - JOUR

T1 - Challenging the FDA black box warning for high aspirin dose with ticagrelor in patients with diabetes

AU - DiNicolantonio, James J.

AU - Serebruany, Victor L.

PY - 2013/3

Y1 - 2013/3

N2 - Ticagrelor, a novel reversible antiplatelet agent, has a Food and Drug Administration (FDA) black box warning to avoid maintenance doses of aspirin (ASA) .100 mg/daily. This restriction is based on the hypothesis that ASA doses .100 mg somehow decreased ticagrelor's benefit in the Platelet Inhibition and Patient Outcomes (PLATO) U.S. cohort. However, these data are highly postrandomized, come from a very small subgroup in PLATO (57% of patients in the U.S. site), and make no biological sense. Moreover, the ticagrelor-ASA interaction was not significant by any multivariate Cox regression analyses. The Complete Response Review for ticagrelor indicates that for U.S. PLATO patients, an ASA dose .300 mg was not a significant interaction for vascular outcomes. In the ticagrelor-ASA .300 mg cohort, allcause and vascular mortality were not significantly increased (hazard ratio [HR] 1.27 [95% CI 0.84-1.93], P = 0.262 and 1.39 [0.87-2.2], P = 0.170), respectively. Furthermore, for major adverse cardiovascular events (MACEs), 30-day all-cause mortality, and 30-day vascular mortality, the strongest interaction is the diabetes-ASA interaction. That is, patients who had diabetes had significantly fewer MACEs through study end (0.49 [0.34- 0.63], P <0.0001), significantly less 30-day all-cause mortality (0.33 [0.20-0.56], P <0.0001), and significantly less 30-day vascular mortality (0.35 [0.22-0.55], P <0.0001), respectively, when given high-dose (300-325 mg) ASA, regardless of treatment (clopidogrel or ticagrelor) assignment. The black box warning for the use of maintenance ASA doses .100 mg with ticagrelor is inappropriate for patients with diabetes and not evidence based.

AB - Ticagrelor, a novel reversible antiplatelet agent, has a Food and Drug Administration (FDA) black box warning to avoid maintenance doses of aspirin (ASA) .100 mg/daily. This restriction is based on the hypothesis that ASA doses .100 mg somehow decreased ticagrelor's benefit in the Platelet Inhibition and Patient Outcomes (PLATO) U.S. cohort. However, these data are highly postrandomized, come from a very small subgroup in PLATO (57% of patients in the U.S. site), and make no biological sense. Moreover, the ticagrelor-ASA interaction was not significant by any multivariate Cox regression analyses. The Complete Response Review for ticagrelor indicates that for U.S. PLATO patients, an ASA dose .300 mg was not a significant interaction for vascular outcomes. In the ticagrelor-ASA .300 mg cohort, allcause and vascular mortality were not significantly increased (hazard ratio [HR] 1.27 [95% CI 0.84-1.93], P = 0.262 and 1.39 [0.87-2.2], P = 0.170), respectively. Furthermore, for major adverse cardiovascular events (MACEs), 30-day all-cause mortality, and 30-day vascular mortality, the strongest interaction is the diabetes-ASA interaction. That is, patients who had diabetes had significantly fewer MACEs through study end (0.49 [0.34- 0.63], P <0.0001), significantly less 30-day all-cause mortality (0.33 [0.20-0.56], P <0.0001), and significantly less 30-day vascular mortality (0.35 [0.22-0.55], P <0.0001), respectively, when given high-dose (300-325 mg) ASA, regardless of treatment (clopidogrel or ticagrelor) assignment. The black box warning for the use of maintenance ASA doses .100 mg with ticagrelor is inappropriate for patients with diabetes and not evidence based.

UR - http://www.scopus.com/inward/record.url?scp=84874409255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874409255&partnerID=8YFLogxK

U2 - 10.2337/db12-0746

DO - 10.2337/db12-0746

M3 - Article

VL - 62

SP - 669

EP - 671

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 3

ER -